

## Federico Martín Torres

Born in Orense (Spain) in 1971, Federico Martín-Torres, MD, PhD, is Head of Translational Paediatrics and Infectious Diseases at the Hospital Clínico Universitario de Santiago (Spain), Associate Professor in Pediatrics and Academic of the Royal Academy of Medicine and Surgery of Galicia. He graduated at the University of Santiago de Compostela and completed his medical training at the Hope Children's Hospital of Chicago and at the Children's Memorial Hospital of Chicago, before obtaining a PhD on the application of heliox in infants with bronchiolitis (awarded the national PhD prize). He has been granted over 25 prizes and awards to academic merits, including Best National Graduate in Medicine and Surgery (1995) and Best National Resident of all sub-specialities (2000). FMT has published more than 300 papers mainly in Q1/D1 journals with a **cumulated impact factor > 450 (JCR2015)**, 70 books and 100 chapters in refereed journals and books. He has delivered more than 300 lectures in over 30 countries. His main research interests are: vaccines, infectious diseases, meningococcal disease, heliox therapy, bronchiolitis, noninvasive ventilation, high frequency oscillatory ventilation, and vasovagal syncope. has directly managed or conducted as PI more than 35 competitive research projects, 30 phase 1 to 3 vaccine clinical trials, and 15 collaborative grants related to infectious diseases and genomics. FMT presently coordinates the clinical network of the FP7 funded EUCLIDS project (GA279185 – [www.euclids-project.eu](http://www.euclids-project.eu)), co-coordinates the pediatric network of the FP7 PREPARE project (GA 602525 –[www.prepare-europe.eu](http://www.prepare-europe.eu)) and the CDP design and preclinical development of new pediatric POC diagnostic device for respiratory syncytial virus based on nanotechnology (PoC-ID project, GA 634415, H2020 2015-2019). FMT also coordinates the H2020 funded PERFORM clinical network (GA 668303). FMT coordinates the national network on translational research on infectious diseases (RITIP), Meningococcal disease network (ESIGEM network - [www.esigem.org](http://www.esigem.org)), the Primary care Pediatric Research Network (ReGALIP; [www.regalip.org](http://www.regalip.org)), the Respiratory Infection Research network (GENDRES; [www.gendres.org](http://www.gendres.org)), the SERGAS Vaccine Research Unit and the Pediatric Research Group (GENVIP) of the Santiago Healthcare Research Institute ([www.genvip.org](http://www.genvip.org)). FMT is also board member of ReSVinet ([www.resvinet.org](http://www.resvinet.org)) an international network on RSV infection. FMT controls and administer the biobank of EUCLIDS consortium.

**SERGAS Clinical Trial Unit** has extensive experience (more than 45 phase 1 to phase 3 trials) leading mainly but not exclusively vaccine clinical trials of different candidates (RSV-PI3, 13&15 valent pneumococcal, 9-valent HPV, meningococcus B (4cMenB and rLP2086), tetravalent flu vaccines, among others), from phase 1, in neonatal and paediatric patients.

On January 2015 the Clinical Trial Unit received the INSPIRE accreditation from Pfizer and PAREXEL has also included this unit in its excellence alliance group.

**GENVIP** has extensive collaborative experience in big scale multicentre studies related to infectious diseases and “omics”. They have created and coordinate the Spanish Network for Meningococcal research –ESIGEM network -involving 40 centres and 120 sub-investigators). They also conduct the Spanish national network for respiratory infections research –GENDRES network- involving 12 centres and 45 sub-investigators. The group shares stable collaborative research lines in genomics and transcriptomics with Imperial College of London (M. Levin / J. Herberg), Genomic Institute of Singapore (M. Hibberd / S. Davila), Raboud University (R. de Groot / M. de Jonge), Oxford Gene Technology (J. Clough), Sistemas Genomicos, and Nationwide Children's Hospital in Ohio (O. Ramilo / A. Mejias).